Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Helena A. Yu, MD, and Maria E. Arcila, MD, provide medical oncology and pathology perspectives, respectively, on new data from ESMO 2020 informing precision medicine in NSCLC, with topics including:
Presenters:
Helena A. Yu, MD
Assistant Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Maria E. Arcila, MD
Pathologist
Director, Diagnostic Molecular Pathology Laboratory
Memorial Sloan Kettering Cancer Center
New York, New York
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.
Read expert insights on best practices for incorporating immune checkpoint inhibitor therapy for patients with NSCLC, from Clinical Care Options (CCO)
On-demand webcast from a live satellite symposium at SITC 2022 on current use of IO therapy in lung cancer, from Clinical Care Options (CCO)
Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered lung and thyroid cancer
Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.